Top Markets
Coin of the day
Boundless Bio, Inc. Boundless Bio, Inc.

Boundless Bio, Inc.

BOLD
Hisse Senetlerindeki Sıralama #23919
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing... Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Hisse Fiyatı
$3.00
Son senkronizasyon: 2026-08-21
Piyasa Değeri
$67.31M
Değişim (1 gün)
3.28%
Değişim (1 yıl)
155.98%
Ülke
US
Ticaret Boundless Bio, Inc. (BOLD)

Kategori

Boundless Bio, Inc. (BOLD) için temettü verimi geçmişi
Boundless Bio, Inc. (hisse sembolü: BOLD) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Boundless Bio, Inc. (BOLD) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH